Discovery of Rapid-Acting, Orally Available Antidepressants by Activating TrkB Signaling.
Abstract
Major depressive disorder (MDD) remains a significant global health burden, and its current treatments are limited by the delayed onset of efficacy weeks after dosing. While esketamine and psychedelics were clinically successful as rapid-acting antidepressants in recent years, these molecules are heavily associated with psychotic side effects and the risks of substance abuse. In this study, we identified a rapid-acting antidepressant <b>B11</b> through phenotypic screening and pharmacophore-oriented lead optimization. Unlike the existing fast-onset antidepressants, <b>B11</b> showed minimal interference with targets associated with psychotic side effects while demonstrating potent antidepressant effects through activation of the TrkB-CREB signaling axis in preclinical models. Besides, <b>B11</b> readily penetrates the blood-brain barrier and possesses a favorable pharmacokinetic profile that enables oral administration. Our findings highlight the potential of optimized fast-onset therapeutics for addressing unmet clinical needs in depression treatment and underscore the importance of neuroplasticity modulation in drug discovery efforts for MDD.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.